Blog
![cannabisforum_linneo](https://linneohealth.com/wp-content/uploads/2023/11/cannabisforum_linneo.jpg)
Spain: seventh world power in medical cannabis production, but none of it for Spanish patients.
Since 2020, when the UN reclassified cannabis in the list of narcotics from Schedule I (prohibited substance) to Schedule IV
![cannabisforum_linneo](https://linneohealth.com/wp-content/uploads/2023/11/cannabisforum_linneo-1.jpg)
Exploring the European Medical Cannabis Landscape: Reflecting on Cannabisforum 2023
Chief Executive Officer of Linneo Health, Don Bellamy, and Regulatory Affairs Director, MarĆa Ćngeles MuƱoz MarĆn share insights from this
![linneo_talento](https://linneohealth.com/wp-content/uploads/2023/11/linneo_talento.jpg)
Onboarding Talent with our Internship Programme
Last year we shared the experience of our first intern, MĆ³nica MuƱoz, who provided an insight into her time at
![linneo_angeles](https://linneohealth.com/wp-content/uploads/2023/03/linneo_angeles.jpg)
Q&A with MarĆa Angeles, Quality and Regulatory Affairs Director
1. Can you tell us about your background and what led you to the pharmaceutical industry? My first interest in
![LinneoHealth_vmundial](https://linneohealth.com/wp-content/uploads/2023/01/LinneoHealth_vmundial-1.jpg)
Exploring the European Cannabis Market ā Q&A with Don Bellamy
1.Can you give me some background on how Linneo Health got involved in the cannabis industry? Linneo is an independent
![impacto-medioambiental](https://linneohealth.com/wp-content/uploads/2022/11/LinneoHealth-impacto-medioambiental-1.jpg)
Minimising the impact of our business on the environment
By Marta Mora, Environmental Officer, Linneo Health Despite its relatively young age, the cannabis industry, particularly those involved in the